Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Octreotide - Novartis

Drug Profile

Octreotide - Novartis

Alternative Names: Octreotide acetate; Octreotide hydrochloride; Octreotide LAI; Octreotide Long Acting Injectable; Octreotide pamoate; Oncolar; Sandostatin LAR Depot; SMS 201995 ac; SMS 201995 pa; SMS 201995 pa LAR; SMS pa; SMS-201-995; SMS-995; SMS-995-AAA

Latest Information Update: 11 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Novartis
  • Class Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies; Indoles; Somatostatins
  • Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly; Intestinal obstruction; Malignant carcinoid syndrome; Neuroendocrine tumours
  • Discontinued Diabetic retinopathy; Diarrhoea; Polycystic liver disease; Prostate cancer; Thymoma

Most Recent Events

  • 11 May 2020 CASI Pharmaceuticals plans a clinical trial forNeuroendocrine tumours or Acromegaly in China in 2020
  • 16 Mar 2020 CASI Pharmaceuticals announces intention to obtain marketing approval for Acromegaly and Neuroendocrine tumours in China
  • 07 Jan 2020 Discontinued - Phase-II for Neuroendocrine tumours in USA (IM)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top